Lipoprotein(a), the rediscovered risk factor, or how to get "back to the future".
File(s)Lpa-EDITORIAL-2020-March02.docx (94.27 KB)
Accepted version
Author(s)
Sabouret, Pierre
Angoulvant, Denis
Ray, Kausik K
Type
Journal Article
Date Issued
2020-03-20
Date Acceptance
2020-03-05
Citation
Archives of Cardiovascular Diseases, 2020, 113 (3), pp.147-151
ISSN
1875-2136
Publisher
Elsevier
Start Page
147
End Page
151
Journal / Book Title
Archives of Cardiovascular Diseases
Volume
113
Issue
3
Copyright Statement
© 2020 Elsevier Ltd. All rights reserved. This manuscript is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licence http://creativecommons.org/licenses/by-nc-nd/4.0/
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/32205042
PII: S1875-2136(20)30059-0
Subjects
AKCEA-APO(a)-L(Rx)
AKCEA-APO(a)-LRX
Inhibiteurs des PCSK9
Lipid-lowering treatments
Lipoprotein(a)
Lp(a)
PCSK9 inhibitors
Residual risk
Risque résiduel
Traitements hypolipémiants
Publication Status
Published
Coverage Spatial
Netherlands
Date Publish Online
2020-03-20